[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447598":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":10,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (medical records review)",null,"Patients' medical records are reviewed.",[13],"Other: Electronic Health Record Review",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Electronic Health Record Review","Medical records are reviewed",[9],[20],{"name":21,"affiliation":5,"role":22},"Nicolas L Palaskas","PRINCIPAL_INVESTIGATOR",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-95.36327,29.76328,{"lat":36,"lon":35},[39,44],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Nicolas L. Palaskas","CONTACT","713-563-3532","nlpalaskas@mdanderson.org",{"name":40,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100447598","complications-and-clinical-response-in-cancer-patients-treated-with-anti-vegf-related-therapies-100447598",false,"NCT05108519","Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","Inclusion Criteria:\n\n* Patients must be able to understand and be willing to sign a written informed consent document\n* Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy","ALL",{"count":56,"type":57},170,"ESTIMATED","OBSERVATIONAL","This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.",[61,62],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","2026-02-17",{"date":65,"type":66},"2026-02-19","ACTUAL",{"date":68,"type":66},"2019-04-08",{"date":70,"type":57},"2027-02-02",{"name":5,"class":6},1]